These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 17908180)
41. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas. Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687 [TBL] [Abstract][Full Text] [Related]
42. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma. Ömür Ö; Baran Y; Oral A; Ceylan Y Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817 [TBL] [Abstract][Full Text] [Related]
43. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911 [TBL] [Abstract][Full Text] [Related]
44. FDG-PET/ CT for initial staging and response assessment in Castleman disease - retrospective single-center study of 29 cases. Koukalová R; Selingerová I; Řehák Z; Adam Z; Szturz P Klin Onkol; 2021; 34(2):120-127. PubMed ID: 33906360 [TBL] [Abstract][Full Text] [Related]
45. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma. Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904 [TBL] [Abstract][Full Text] [Related]
46. Coexistence of Hodgkin's Lymphoma and Castleman's Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy. Mohtaram A; Afif M; Sghiri T; Rami A; Latib R; Kettani F; Ben Ameur El Youbi M; Boutayeb S; Kebdani T; Benjaafar N; Aaribi I; Errihani H Case Rep Oncol Med; 2013; 2013():487205. PubMed ID: 24381772 [TBL] [Abstract][Full Text] [Related]
48. Prognostic significance of pretreatment ¹⁸F-FDG PET/CT in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma treated by radioimmunotherapy using ¹³¹I-rituximab. Lim I; Park JY; Kang HJ; Hwang JP; Lee SS; Kim KM; Choi TH; Yang SH; Kim BI; Choi CW; Lim SM Acta Haematol; 2013; 130(2):74-82. PubMed ID: 23548464 [TBL] [Abstract][Full Text] [Related]
49. [Primary non-Hodgkin lymphoma of the liver: case report and review of the literature]. Nasr Ben Ammar C; Chaari N; Kochbati L; Besbes M; Maalej M Cancer Radiother; 2006 Dec; 10(8):595-601. PubMed ID: 17137818 [TBL] [Abstract][Full Text] [Related]
50. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Herrmann K; Wieder HA; Buck AK; Schöffel M; Krause BJ; Fend F; Schuster T; Meyer zum Büschenfelde C; Wester HJ; Duyster J; Peschel C; Schwaiger M; Dechow T Clin Cancer Res; 2007 Jun; 13(12):3552-8. PubMed ID: 17575218 [TBL] [Abstract][Full Text] [Related]
51. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. Martelli M; Ceriani L; Zucca E; Zinzani PL; Ferreri AJ; Vitolo U; Stelitano C; Brusamolino E; Cabras MG; Rigacci L; Balzarotti M; Salvi F; Montoto S; Lopez-Guillermo A; Finolezzi E; Pileri SA; Davies A; Cavalli F; Giovanella L; Johnson PW J Clin Oncol; 2014 Jun; 32(17):1769-75. PubMed ID: 24799481 [TBL] [Abstract][Full Text] [Related]
52. [Two HHV8-related illnesses in a HIV-negative patient: Kaposi's sarcoma and multicentric Castleman's disease. Response to treatment with Rituximab and CHOP]. Pastor MA; Vasco B; Mosquera JM; Debén G; Bautista P; Requena L Actas Dermosifiliogr; 2006; 97(6):385-90. PubMed ID: 16956518 [TBL] [Abstract][Full Text] [Related]
53. Successfully treated multicentric Castleman's disease with renal thrombotic microangiopathy using rituximab and corticosteroid. Lee JP; Kim DK; Oh DY; Paik JH; Moon KC; Kim S; Kim YS Clin Nephrol; 2011 Feb; 75(2):165-70. PubMed ID: 21255547 [TBL] [Abstract][Full Text] [Related]
54. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046 [TBL] [Abstract][Full Text] [Related]
56. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission. Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504 [TBL] [Abstract][Full Text] [Related]
57. Transformation of Hodgkin's disease to high-grade B-cell lymphoma: remission after Rituximab monotherapy. Kirchner EM; Ebsen M; Kirchner J; Theegarten D; Voigtmann R Ann Oncol; 2001 Aug; 12(8):1169-71. PubMed ID: 11583202 [TBL] [Abstract][Full Text] [Related]
58. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. Guay C; Lépine M; Verreault J; Bénard F J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411 [TBL] [Abstract][Full Text] [Related]